Fueling Next-Generation MS Disease Progression Research with Valhalla Foundation Support – Read the Release

OCTAVE EVENTS

Sep 24 - 26, 2025
Barcelona, Spain

Octave at ECTRIMS 2025

Biomarker Research in Multiple Sclerosis by Octave and Collaborators

P1544Characterizing Protein and MSDA Score Correlations Amongst Stable Participants from the Measuring Outcomes and Value: an Integrated, Novel Solution for Generating insights in MS (MOVING MS) Study

P263 Characterizing MSDA Score and MSDA Panel Biomarker Associations with Disease Activity and Progression Measures in the Graz MS Study

P1528Real-world Utilization of a Novel Multi-analyte Blood-Based Biomarker Panel, the Octave® Multiple Sclerosis Disease Activity (MSDA) Test In Clinical Practice Across the United States

P767 Blood Protein Profiles are associated with Brain Atrophy in Multiple Sclerosis

P1533Choroid Plexus Volume and Blood-based Protein Profiles to Monitor Brain Atrophy in Multiple Sclerosis

P236 Temporal Dynamics of Proteomic Profiling in Multiple Sclerosis: Insights from a Retrospective Longitudinal Study

P1947Three-Year Findings on the Safety and Efficacy of Cladribine Tablets after Treatment with Natalizumab (CLADRINA Extension Study)
P815 – High-Dose N-Acetyl Cysteine Stabilizes GFAP Levels: Results from a Pilot Double-blind, Placebo-Controlled Randomized Trial

P764 – Emerging cerebrospinal fluid and serum biomarkers in multiple sclerosis: Cytokines, MOG, GFAP and beyond

Connect with Octave